Literature DB >> 7930752

Successes and failures in measles control.

F T Cutts1, L E Markowitz.   

Abstract

The Expanded Programme on Immunization (EPI) of the World Health Organization has a global target of reducing measles incidence by 90% and mortality by 95% from pre-EPI levels by 1995. Both developed and developing countries that have given priority to measles control have substantially reduced measles morbidity and mortality, and some have come close to eliminating measles. A variety of vaccination schedules and strategies have been used, which reflect the differing program goals, health services infrastructure, and availability of resources in different countries. Failure to control measles has usually been due to a failure to implement planned strategies adequately. The highest priority in measles control is to assist countries, especially the lowest-income countries, to implement vaccination programs more effectively.

Mesh:

Substances:

Year:  1994        PMID: 7930752     DOI: 10.1093/infdis/170.supplement_1.s32

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  33 in total

1.  Analysis of the noncoding regions of measles virus strains in the Edmonston vaccine lineage.

Authors:  C L Parks; R A Lerch; P Walpita; H P Wang; M S Sidhu; S A Udem
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Comparison of predicted amino acid sequences of measles virus strains in the Edmonston vaccine lineage.

Authors:  C L Parks; R A Lerch; P Walpita; H P Wang; M S Sidhu; S A Udem
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.

Authors:  Evanthia Galanis; Pamela J Atherton; Matthew J Maurer; Keith L Knutson; Sean C Dowdy; William A Cliby; Paul Haluska; Harry J Long; Ann Oberg; Ileana Aderca; Matthew S Block; Jamie Bakkum-Gamez; Mark J Federspiel; Stephen J Russell; Kimberly R Kalli; Gary Keeney; Kah Whye Peng; Lynn C Hartmann
Journal:  Cancer Res       Date:  2014-11-14       Impact factor: 12.701

Review 4.  Oncolytic measles virus strains in the treatment of gliomas.

Authors:  Cory Allen; Georgia Paraskevakou; Chunsheng Liu; Ianko D Iankov; Pavlos Msaouel; Paula Zollman; Rae Myers; Kah Whye Peng; Stephen J Russell; Evanthia Galanis
Journal:  Expert Opin Biol Ther       Date:  2008-02       Impact factor: 4.388

Review 5.  Should measles be eradicated?

Authors:  F T Cutts; R Steinglass
Journal:  BMJ       Date:  1998-03-07

6.  [A survey on vaccine efficacy in the city of Bongor (Chad) and its operational consequences for the vaccination program].

Authors:  J C Luthi; W Kessler; M Boelaert
Journal:  Bull World Health Organ       Date:  1997       Impact factor: 9.408

7.  Preventing epidemics in a community of households.

Authors:  R Hall; N G Becker
Journal:  Epidemiol Infect       Date:  1996-12       Impact factor: 2.451

8.  Second dose of measles, mumps, and rubella vaccine: questionnaire survey of health professionals.

Authors:  M Petrovic; R Roberts; M Ramsay
Journal:  BMJ       Date:  2001-01-13

9.  Identifying high-risk areas for sporadic measles outbreaks: lessons from South Africa.

Authors:  Benn Sartorius; C Cohen; T Chirwa; G Ntshoe; A Puren; K Hofman
Journal:  Bull World Health Organ       Date:  2013-01-11       Impact factor: 9.408

10.  Identification and characterization of novel, naturally processed measles virus class II HLA-DRB1 peptides.

Authors:  Inna G Ovsyannikova; Kenneth L Johnson; David C Muddiman; Robert A Vierkant; Gregory A Poland
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.